Skip to main content
. 2024 Oct 8;43(4):403–411. doi: 10.1200/JCO.24.00533

TABLE A2.

TEAEs by Treatment Arm

Description Arm A (ramucirumab + osimertinib), No. (%) Arm B (osimertinib), No. (%)
G1 G2 G3 G4 Any Grade G1 G2 G3 Any Grade
Diarrhea 52 (55.9) 11 (11.8) 3 (3.2) 0 66 (71.0) 25 (54.4) 5 (10.9) 0 30 (65.2)
Skin rash 46 (49.5) 10 (10.8) 1 (1.1) 0 57 (61.3) 25 (54.4) 1 (2.2) 1 (2.2) 27 (58.7)
Fatigue 42 (45.2) 10 (10.8) 3 (3.2) 0 55 (59.1) 15 (32.6) 4 (8.7) 0 19 (41.3)
Headache 37 (39.8) 9 (9.7) 0 0 46 (49.5) 7 (15.2) 1 (2.2) 0 8 (17.4)
Cough 36 (38.7) 10 (10.8) 0 0 46 (49.5) 8 (17.4) 2 (4.4) 0 10 (21.7)
Epistaxis 38 (40.9) 3 (3.2) 0 0 41 (44.1) 3 (6.5) 0 0 3 (6.5)
Paronychia 30 (32.3) 8 (8.6) 0 0 38 (40.9) 13 (28.3) 0 0 14 (30.4)
Anorexia 24 (25.8) 10 (10.8) 0 0 34 (36.6) 3 (6.5) 1 (2.2) 1 (2.2) 5 (10.9)
Hypertension 3 (3.2) 10 (10.8) 21 (22.6) 0 34 (36.6) 1 (2.2) 4 (8.7) 1 (2.2) 6 (13.0)
Platelet count decreased 22 (23.7) 11 (11.8) 1 (1.1) 0 34 (36.6) 7 (15.2) 0 1 (2.2) 8 (17.4)
Dry skin 30 (32.3) 2 (2.2) 0 0 32 (34.4) 11 (23.9) 1 (2.2) 0 12 (26.1)
Nausea 28 (30.1) 4 (4.3) 0 0 32 (34.4) 6 (13.0) 1 (2.2) 0 7 (15.2)
Alopecia 25 (26.9) 3 (3.2) 0 0 28 (30.1) 10 (21.7) 0 0 10 (21.7)
Anemia 21 (22.6) 2 (2.2) 3 (3.2) 0 26 (28.0) 6 (13.0) 1 (2.2) 2 (4.4) 9 (19.6)
Pain in extremity 19 (20.4) 7 (7.5) 0 0 26 (28.0) 5 (10.9) 2 (4.4) 0 7 (15.2)
Back pain 15 (16.1) 8 (8.6) 2 (2.2) 0 25 (26.9) 8 (17.4) 1 (2.2) 0 9 (19.6)
Dyspnea 16 (17.2) 7(7.5) 1 (1.1) 0 24 (25.8) 4 (8.7) 5 (10.9) 1 (2.2) 10 (21.7)
WBC decreased 19 (20.4) 5 (5.4) 0 0 24 (25.8) 3 (6.5) 2 (4.4) 0 5 (10.9)
Pruritus 22 (23.7) 2 (2.2) 0 0 24 (25.8) 3 (6.5) 0 1 (2.2) 4 (8.7)
Vomiting 19 (20.4) 5 (5.4) 0 0 24 (25.8) 2 (4.4) 1 (2.2) 0 3 (6.5)
Hyponatremia 13 (14.0) 4 (4.3) 2 (2.2) 1 (1.1) 20 (21.5) 7 (15.2) 0 1 (2.2) 8 (17.4)
Proteinuria 5 (5.4) 11 (11.8) 2 (2.2) 0 18 (19.4) 0 1 (2.2) 0 1 (2.2)

Abbreviations: G, grade; TEAEs, treatment-emergent adverse events.